Recipharm AB: Announcement from the nomination committee concerning the Annual General Meeting 2015

Regulatory News:

Recipharm’s (STO: RECI) nomination committee proposes that Carlos von Bonhorst be elected as a new board member. The nomination committee also proposes re-election of all board members: Marianne Dicander Alexandersson, Lars Backsell, Anders G. Carlberg, Thomas Eldered, Göran Pettersson, Tony Sandell and Joan Traynor.

Re-election of Lars Backsell as chairman of the board is furthermore proposed.

Carlos von Bonhorst has held several leading positions in the European pharmaceuticals industry and as a scientific expert and advisor to boards and management teams in the field of pharmaceuticals. Carlos von Bonhorst holds a degree in medicine from the Universidade Clássica de Lisboa (Lisbon), and has also worked as a physician. He was born in 1957, grew up in Portugal and currently lives in Brussels, Belgium.

The nomination committee has comprised Per Lundborg, chairman (appointed by B & E Participation AB), Lars Backsell (chairman of the board of Recipharm), Johan Lannebo (appointed by Lannebo Fonder) and Frank Larsson (appointed by Handelsbanken Fonder).

The nomination committee’s other proposals regarding chairs of meetings, fees and how the nomination committee is to be appointed will be published on the website and announced in the notice of the AGM.

Recipharm’s Annual General Meeting will be held on 7 May 2015 at 2pm on Recipharm AB’s premises at Lagervägen 7, 136 50 Jordbro, Sweden.

About Recipharm

Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com

This information was brought to you by Cision http://news.cision.com